700 related articles for article (PubMed ID: 16028280)
1. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
2. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
5. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB
Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633
[TBL] [Abstract][Full Text] [Related]
9. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
13. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
14. Merkel cell carcinoma: an unusual indication for isolated limb perfusion.
Ponte P; Moniz JV; Farricha V; Weinholtz JB
Dermatol Online J; 2008 Jul; 14(7):6. PubMed ID: 18718190
[TBL] [Abstract][Full Text] [Related]
15. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
16. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
[TBL] [Abstract][Full Text] [Related]
17. TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for modification of the perfusional schedule.
Rossi CR; Foletto M; Mocellin S; Pilati PL; Campana L; Rubello D; Lise M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):103-7. PubMed ID: 16767915
[TBL] [Abstract][Full Text] [Related]
18. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]